Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Phase 2

Recruiting

Conditions: Small Cell Carcinoma of the Bladder
Squamous Cell Carcinoma of the Urinary Tract
Small Cell Carcinoma of the Urinary Tract
Renal Medullary Carcinoma
Primary Adenocarcinoma of the Bladder
Primary Adenocarcinoma of the Urinary Tract
Squamous Cell Carcinoma of the Bladder
Squamous Cell Carcinoma of the Penis

Interventions: Drug: Sacituzumab govitecan
Drug: Atezolizumab

First Posted Date: 2023-12-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06161532

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma Non-resectable

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Radiation: Proton radiotherapy

First Posted Date: 2023-11-15

Last Posted Date: 2024-02-07

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 45

Registration Number: NCT06133062

Locations: 🇨🇳
Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Drug: Durvalumab
Drug: Tremelimumab,

First Posted Date: 2023-11-07

Last Posted Date: 2024-11-21

Lead Sponsor: Bayer

Target Recruit Count: 300

Registration Number: NCT06117891

Locations: 🇺🇸
Mercy Medical Center - Medline Healthcare Services LLC, Baltimore, Maryland, United States
🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 4 locations

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Livmoniplimab
Drug: Atezolizumab
Drug: Durvalumab
Drug: Budigalimab
Drug: Tremelimumab
Drug: Bevacizumab

First Posted Date: 2023-10-31

Last Posted Date: 2024-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 660

Registration Number: NCT06109272

Locations: 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy
🇺🇸
City of Hope /ID# 261468, Duarte, California, United States
🇺🇸
City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States

and more 34 locations

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2023-10-24

Last Posted Date: 2024-08-28

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 120

Registration Number: NCT06096779

Locations: 🇺🇸
University of Southern California; Oncology/Hematology, Newport Beach, California, United States
🇺🇸
Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS, Pittsburgh, Pennsylvania, United States
🇺🇸
Kelsey Research Foundation, Houston, Texas, United States

and more 40 locations

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1

Withdrawn

Conditions: Advanced Solid Tumor
Urothelial Carcinoma Bladder
Melanoma
Gastric Cancer
CDKN2A
NSCLC
HNSCC
Renal Cell Carcinoma
Mesothelioma
Pancreas Adenocarcinoma

Interventions: Drug: Milademetan
Drug: Atezolizumab

First Posted Date: 2023-10-19

Last Posted Date: 2023-10-19

Lead Sponsor: Rain Oncology Inc

Registration Number: NCT06090318

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: BI 764532
Drug: Etoposide
Drug: Carboplatin
Drug: Cisplatin
Drug: Durvalumab
Drug: Atezolizumab

First Posted Date: 2023-10-11

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06077500

Locations: 🇪🇸
Hospital Virgen Macarena, Sevilla, Spain
🇧🇪
Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷
INS Bergonie, Bordeaux, France

and more 11 locations